Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SONO

Sonos Inc

Feb 13 • 04:00PM ET

15.51

-0.78 -4.79 %

Technology • Consumer Electronics • USA • NASD

Peers: AAPL GOOGL AMZN LGF-A BHE LOGI DENN ALGM UEIC VZ

| Held by: IJR VTI IWM VB VBK VXF FESM SPSM IJT IWO

Index	RUT	P/E	-	EPS (ttm)	-0.17	Insider Own	1.56%	Shs Outstand	123.87M	Perf Week	-9.19%
Market Cap	1.87B	Forward P/E	55.39	EPS next Y	0.28	Insider Trans	71.08%	Shs Float	118.99M	Perf Month	-4.26%
Enterprise Value	1.57B	PEG	-	EPS next Q	-0.24	Inst Own	95.58%	Short Float	9.14%	Perf Quarter	-9.35%
Income	-17.58M	P/S	1.30	EPS this Y	161.76%	Inst Trans	-0.38%	Short Ratio	6.42	Perf Half Y	17.68%
Sales	1.44B	P/B	4.33	EPS next Y	-11.11%	ROA	-1.84%	Short Interest	10.88M	Perf YTD	-11.67%
Book/sh	3.58	P/C	5.16	EPS next 5Y	-	ROE	-3.85%	52W High	19.82 -21.75%	Perf Year	17.77%
Cash/sh	3.01	P/FCF	15.41	EPS past 3/5Y	- -22.55%	ROIC	-3.55%	52W Low	7.62 103.41%	Perf 3Y	-26.87%
Dividend Est.	-	EV/EBITDA	15.42	Sales past 3/5Y	-6.26% 1.70%	Gross Margin	44.92%	Volatility	6.93% 5.61%	Perf 5Y	-56.29%
Dividend TTM	-	EV/Sales	1.09	EPS Y/Y TTM	73.45%	Oper. Margin	3.00%	ATR (14)	0.91	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.33	Sales Y/Y TTM	-1.23%	Profit Margin	-1.22%	RSI (14)	43.97	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.65	EPS Q/Q	86.79%	SMA20	-0.47%	Beta	1.94	Target Price	20.00
Payout	-	Debt/Eq	0.13	Sales Q/Q	-0.94%	SMA50	-8.53%	Rel Volume	1.88	Prev Close	16.29
Employees	1404	LT Debt/Eq	0.12	Earnings	Feb 03 AMC	SMA200	8.99%	Avg Volume	1.69M	Price	15.51
IPO	Aug 02, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.19% 1.63%	Trades		Volume	3,180,857	Change	-4.79%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$17
Sep-26-24	Downgrade	Morgan Stanley	Overweight → Underweight	$25 → $11
Aug-08-24	Downgrade	Craig Hallum	Buy → Hold	$25 → $10
Dec-12-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$17 → $20
Nov-07-23	Downgrade	BofA Securities	Buy → Neutral	$20 → $12
Sep-20-23	Initiated	Rosenblatt	Buy	$20
Sep-08-23	Initiated	Craig Hallum	Buy	$20
Jun-15-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $28
Aug-16-21	Upgrade	Jefferies	Hold → Buy	$43 → $50
Feb-12-21	Upgrade	Goldman	Sell → Neutral	$17 → $37
Oct-15-20	Upgrade	BofA Securities	Neutral → Buy	$18
Jul-29-20	Downgrade	Raymond James	Strong Buy → Mkt Perform
Apr-17-20	Downgrade	Goldman	Buy → Sell	$20 → $7.50
Feb-25-20	Initiated	BofA/Merrill	Neutral	$15
Nov-13-19	Initiated	RBC Capital Mkts	Outperform
Aug-19-19	Upgrade	Raymond James	Outperform → Strong Buy	$19
Apr-02-19	Initiated	DA Davidson	Buy
Jan-28-19	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-27-18	Initiated	RBC Capital Mkts	Outperform	$25
Aug-27-18	Initiated	Raymond James	Outperform

Show Previous Ratings

Feb-10-26 12:32AM	The Top 5 Analyst Questions From Sonos's Q4 Earnings Call (StockStory)
Feb-09-26 08:35AM	Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack (24/7 Wall St.)
Feb-05-26 12:09PM	PTC Q1 Earnings & Revenues Top, Rise Y/Y on Large Deal Momentum (Zacks) +6.43%
12:06PM	SONY Q3 Earnings & Sales Up Y/Y on I&SS Momentum, FY25 Outlook Raised (Zacks)
02:00AM	With reliability restored, Sonos focuses on customer advocacy (CX Dive)
08:06PM	Loading…
Feb-04-26 08:06PM	Sonos Inc (SONO) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges (GuruFocus.com) +6.36%
01:11PM	Why Sonos Stock Popped Today (Motley Fool)
12:25PM	Why Sonos (SONO) Stock Is Up Today (StockStory)
10:03AM	Stocks Mixed on Sector Rotation out of Tech (Barchart)
09:10AM	Sonos Q1 Earnings and Revenues Surpass Estimates, Stock Rises (Zacks)
12:32AM	SONO Q4 Deep Dive: Product Roadmap and Cost Discipline Drive Improved Margins and Outlook (StockStory)
Feb-03-26 08:09PM	Sonos Q1 Earnings Call Highlights (MarketBeat)
05:45PM	Sonos (SONO) Q1 2026 Earnings Call Transcript (Motley Fool)
05:15PM	Sonos (SONO) Q1 Earnings and Revenues Beat Estimates (Zacks)
04:13PM	Sonos's (NASDAQ:SONO) Q4 CY2025 Sales Top Estimates (StockStory)
04:12PM	Loading…
04:12PM	Sonos: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Sonos Reports First Quarter Fiscal 2026 Results (Business Wire)
Feb-02-26 08:45AM	Sonos Set to Report Q1 Earnings: Here's What You Should Know (Zacks)
Feb-01-26 10:13PM	Sonos (SONO) Q4 Earnings Report Preview: What To Look For (StockStory)
Jan-31-26 09:48AM	Is Sonos Inc. (SONO) One of the Best Small Cap Tech Stocks to Invest in Now? (Insider Monkey)
Jan-29-26 05:55PM	Dolby Laboratories (DLB) Q1 Earnings and Revenues Surpass Estimates (Zacks)
Jan-27-26 11:00AM	Sonos Introduces Amp Multi, a Professional-Grade Multi-Channel Streaming Amplifier Built for Evolving Homes (Business Wire)
Jan-26-26 09:10AM	Sony Expands Wearable Audio With LinkBuds Clip Open Earbuds (Zacks)
Jan-25-26 11:31PM	3 Small-Cap Stocks We Keep Off Our Radar (StockStory)
Jan-20-26 11:26AM	Why Sonos (SONO) Shares Are Trading Lower Today (StockStory)
08:28AM	Sonos Shares Soar 50% in 6 Months: Is There More Upside Ahead? (Zacks)
Jan-16-26 03:45PM	Meet the Sams Club CEO tasked with taking on Costco (FastCompany)
Jan-13-26 04:05PM	Sonos Announces Date for First Quarter Fiscal 2026 Financial Results and Conference Call (Business Wire)
Jan-12-26 04:05PM	Sonos Appoints Carmine Arabia, Mandy Fields and Joe Kennedy to Board of Directors (Business Wire)
Jan-07-26 10:35PM	Q3 Earnings Roundup: Sonos (NASDAQ:SONO) And The Rest Of The Consumer Discretionary Segment (StockStory)
03:06PM	Loading…
Jan-06-26 03:06PM	Why Sonos (SONO) Stock Is Falling Today (StockStory) -5.86%
Jan-05-26 08:55AM	GoPro Shares Jump 93% in 6 Months: Is the Upside Sustainable in 2026? (Zacks)
Jan-04-26 11:00PM	3 Reasons to Sell SONO and 1 Stock to Buy Instead (StockStory)
Dec-29-25 11:33PM	1 Cash-Producing Stock on Our Watchlist and 2 That Underwhelm (StockStory)
Dec-18-25 11:30AM	Why Is Dolby Laboratories (DLB) Up 3.3% Since Last Earnings Report? (Zacks)
Dec-11-25 11:37PM	3 Unpopular Stocks We Find Risky (StockStory)
Dec-09-25 09:45AM	Top Insider Purchases in December Signal Market Confidence (24/7 Wall St.)
Dec-05-25 11:30AM	Sonos (SONO) Up 15.2% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-03-25 04:05PM	Sonos Announces Participation in Raymond James TMT & Consumer Conference (Business Wire)
Nov-24-25 04:55PM	Sonos, ThredUp, RE/MAX, United Airlines, and Acushnet Shares Skyrocket, What You Need To Know (StockStory) +5.13%
02:23PM	Baker Hughes Eyes Buy Point; Watch These Real Estate, Audio Stocks In Bases (Investor's Business Daily)
Nov-19-25 08:20AM	Dolby's Q4 Earnings & Revenues Surpass Estimates, Increase Y/Y (Zacks)
Nov-11-25 07:11AM	SONY Q2 Earnings & Revenues Rise Y/Y, View Up on G&NS & Music Momentum (Zacks)
Nov-09-25 08:01PM	Sonos Inc (SONO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts (GuruFocus.com)
Nov-07-25 08:38AM	GoPro's Q3 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down (Zacks)
Nov-06-25 09:00AM	Sonos Posts Q4 Loss, Revenues Surpass Estimates & Rise Y/Y (Zacks)
08:32AM	Sonos climbs after Morgan Stanley upgrade, says tariff fears overblown (Investing.com)
02:00AM	Sonos wants to be at the center of AI personalities (CX Dive)
Nov-05-25 07:03PM	Sonos Hires a Madison Avenue Veteran to Revive Its Bruised Brand (The Wall Street Journal)
09:20AM	Sonos (SONO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:43AM	Sonos (NASDAQ:SONO) Missed Q3 EPS Expectations; Stock Drops (StockStory)
08:29AM	Sonos: Fiscal Q4 Earnings Snapshot (Associated Press Finance)
08:01AM	Sonos Reports Fourth Quarter and Fiscal 2025 Results (Business Wire)
Nov-04-25 08:21AM	Sonos to Report Q4 Earnings: What Should Investors Expect? (Zacks)
Nov-03-25 10:06PM	What To Expect From Sonos's (SONO) Q3 Earnings (StockStory)
Oct-24-25 12:40AM	1 Unprofitable Stock to Target This Week and 2 We Find Risky (StockStory)
Oct-23-25 12:42AM	1 Cash-Producing Stock to Target This Week and 2 Facing Headwinds (StockStory)
Oct-20-25 12:35AM	3 Cash-Producing Stocks That Fall Short (StockStory)
Oct-15-25 04:01PM	Sonos Announces Date for Fourth Quarter and Fiscal 2025 Financial Results and Conference Call (Business Wire)
08:08AM	3 Small Caps Hitting 52-Week Highs: Take Profits or Let Ride? (MarketBeat)
Oct-10-25 01:06PM	Sonos, Polaris, Funko, 1-800-FLOWERS, and Altice Shares Are Falling, What You Need To Know (StockStory) -6.88%
Oct-09-25 09:48AM	Sonos Up 63% in 3 Months: Where Will the Stock Head From Here? (Zacks)
Oct-03-25 09:40AM	Is SOHO HOUSE&CO (SHCO) Stock Outpacing Its Consumer Discretionary Peers This Year? (Zacks)
Oct-01-25 02:37PM	Peloton Slides After Hiking Prices in Sweeping Product Revamp (Bloomberg)
10:50AM	Peloton Unveils AI Coaching, New Machines To Boost Sales (Benzinga)
Sep-24-25 12:36AM	3 Cash-Heavy Stocks That Fall Short (StockStory)
Sep-23-25 10:34AM	3 Audio Video Stocks to Focus on From a Flourishing Industry (Zacks)
Sep-16-25 12:36AM	3 Small-Cap Stocks That Fall Short (StockStory)
Sep-12-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Sonos (SONO) is a Great Choice (Zacks)
09:50AM	Sonos (SONO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Sep-10-25 11:30AM	Why Is GoPro (GPRO) Up 32.5% Since Last Earnings Report? (Zacks)
Sep-02-25 12:33AM	2 Volatile Stocks with Promising Prospects and 1 Facing Headwinds (StockStory)
Aug-26-25 12:01AM	3 Reasons to Avoid SONO and 1 Stock to Buy Instead (StockStory)
Aug-22-25 04:55PM	GM's Tariff Strategy, New Models, Set It Up for Growth, Analyst Says. Plus, Sonos, Affirm, and More Stocks. (Barrons.com)
Aug-19-25 12:00PM	Sonos (SONO) is a Great Momentum Stock: Should You Buy? (Zacks)
09:50AM	Here's Why Sonos (SONO) is a Strong Momentum Stock (Zacks)
Aug-18-25 12:20PM	Earnings Estimates Rising for Sonos (SONO): Will It Gain? (Zacks) +5.17%
Aug-14-25 04:05PM	Sonos Announces Participation in Rosenblatt Virtual 5th Annual Technology Summit (Business Wire)
03:00AM	Sonos looks to software to improve experience, win back customers (CX Dive)
Aug-13-25 01:33AM	The Top 5 Analyst Questions From Sonos's Q2 Earnings Call (StockStory)
Aug-12-25 11:51AM	Why Is Sonos (SONO) Stock Soaring Today (StockStory) +13.45%
09:10AM	GoPro's Q2 Loss Wider Than Expected, Revenues Down Y/Y (Zacks)
03:06AM	SONO Q2 Deep Dive: Management Focuses on Operational Efficiency, Tariffs, and Platform Evolution (StockStory)
Aug-07-25 10:52AM	Sonos' Q3 Earnings Meet Estimates, Revenues Beat, Stock Up (Zacks)
08:30AM	Sonos is raising prices this year to make up for tariff expenses (Engadget)
Aug-06-25 05:30PM	Sonos (SONO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:19PM	Sonos (NASDAQ:SONO) Delivers Impressive Q2 (StockStory)
05:10PM	Sonos (SONO) Meets Q3 Earnings Estimates (Zacks)
04:09PM	Sonos: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Sonos Reports Third Quarter Fiscal 2025 Results (Business Wire)
Aug-04-25 11:05PM	Sonos Earnings: What To Look For From SONO (StockStory)
01:05PM	Sonos, Lincoln Educational, Wolverine Worldwide, Lovesac, and Xponential Fitness Shares Skyrocket, What You Need To Know (StockStory)
Aug-01-25 10:24AM	Sonos to Announce Q3 Earnings: Here's What You Should Know (Zacks)
Jul-31-25 06:10PM	Dolby Laboratories (DLB) Surpasses Q3 Earnings and Revenue Estimates (Zacks) -5.18%
Jul-24-25 12:36PM	Sonos makes interim CEOs appointment permanent as it works to win back customers (CX Dive)
Jul-23-25 01:31PM	Why Sonos (SONO) Stock Is Up Today (StockStory)
08:00AM	Sonos Appoints Tom Conrad as Chief Executive Officer (Business Wire)
Jul-16-25 04:05PM	Sonos Announces Date for Third Quarter Fiscal 2025 Financial Results and Conference Call (Business Wire)
Jul-11-25 12:50PM	Why Sonos (SONO) Shares Are Trading Lower Today (StockStory) -5.05%
Jul-09-25 10:43AM	LiveOne's Slacker Radio Taps Intuizi to Drive Subscriber Growth (Zacks)

Sonos, Inc. engages in the provision of multi-room wireless audio products. It supports streaming services and provides access to music, Internet radio, podcasts, and audiobooks, with control from Android smartphones, iPhone or iPad. The company was founded by Mai Trung, John MacFarlane, Craig A. Shelburne, and Thomas S. Cullen in 2002 and is headquartered in Santa Barbara, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coliseum Capital Management, L	10% Owner	Feb 04 '26	Buy	15.50	494,719	7,668,144	15,424,999	Feb 06 07:05 PM
Coliseum Capital Management, L	10% Owner	Feb 05 '26	Buy	16.29	211,530	3,445,824	15,636,529	Feb 06 07:05 PM
Coliseum Capital Management, L	10% Owner	Feb 06 '26	Buy	16.49	26,824	442,328	15,663,353	Feb 06 07:05 PM
Lazarus Edward P	Chief Legal & Bus Dev Officer	Dec 04 '25	Sale	19.00	12,000	228,000	423,219	Dec 05 04:40 PM
Lazarus Edward P	Officer	Dec 04 '25	Proposed Sale	19.00	12,000	228,000		Dec 04 09:42 AM
Millington Nicholas	Officer	Dec 03 '25	Proposed Sale	18.89	156,842	2,962,116		Dec 03 04:26 PM
Conrad Thomas	Chief Executive Officer	Nov 17 '25	Buy	16.17	62,325	1,008,045	305,103	Nov 18 09:00 AM
Coliseum Capital Management, L	10% Owner	Aug 07 '25	Buy	10.61	127,406	1,351,778	14,875,280	Aug 11 06:54 PM
Coliseum Capital Management, L	10% Owner	Aug 08 '25	Buy	11.21	55,000	616,550	14,930,280	Aug 11 06:54 PM
Darrell Bracken	Director	Aug 08 '25	Buy	11.15	22,412	250,000	49,452	Aug 11 04:14 PM
Casey Saori	Chief Financial Officer	Aug 08 '25	Buy	10.94	22,727	248,688	107,000	Aug 11 04:11 PM
GENACHOWSKI JULIUS	Director	Aug 08 '25	Buy	10.95	22,850	250,205	124,396	Aug 11 04:09 PM
Conrad Thomas	Chief Executive Officer	Aug 08 '25	Buy	11.10	92,300	1,024,299	242,778	Aug 11 04:07 PM
Coliseum Capital Management, L	10% Owner	Aug 05 '25	Buy	10.83	160,000	1,732,800	14,747,874	Aug 05 06:37 PM
Coliseum Capital Management, L	10% Owner	Aug 01 '25	Buy	10.38	80,000	830,400	14,585,191	Aug 05 06:37 PM
Coliseum Capital Management, L	10% Owner	Aug 04 '25	Buy	10.49	2,683	28,145	14,587,874	Aug 05 06:37 PM
Coliseum Capital Management, L	10% Owner	Jul 29 '25	Buy	11.25	675,000	7,593,750	14,505,191	Jul 29 08:05 PM
Coliseum Capital Management, L	10% Owner	Jul 28 '25	Buy	11.43	350,000	4,000,500	13,830,191	Jul 29 08:05 PM
Coliseum Capital Management, L	10% Owner	Jul 25 '25	Buy	11.18	287,087	3,209,633	13,480,191	Jul 29 08:05 PM
Coliseum Capital Management, L	10% Owner	Jun 20 '25	Buy	9.92	238,000	2,360,960	13,007,676	Jun 24 07:29 PM
Coliseum Capital Management, L	10% Owner	Jun 24 '25	Buy	10.34	111,898	1,157,025	13,193,104	Jun 24 07:29 PM
Coliseum Capital Management, L	10% Owner	Jun 23 '25	Buy	9.89	73,530	727,212	13,081,206	Jun 24 07:29 PM
Coliseum Capital Management, L	10% Owner	Jun 13 '25	Buy	9.93	280,000	2,780,400	12,638,088	Jun 16 07:57 PM
Coliseum Capital Management, L	10% Owner	Jun 12 '25	Buy	10.21	240,000	2,450,400	12,358,088	Jun 16 07:57 PM
Coliseum Capital Management, L	10% Owner	Jun 16 '25	Buy	10.26	131,588	1,350,093	12,769,676	Jun 16 07:57 PM
Coliseum Capital Management, L	10% Owner	Apr 03 '25	Buy	9.17	147,157	1,349,430	12,055,582	Apr 07 08:08 PM
Coliseum Capital Management, L	10% Owner	Apr 07 '25	Buy	8.38	62,506	523,800	12,118,088	Apr 07 08:08 PM

Open in Screener

ARX

Accelerant Holdings

Feb 13 • 04:00PM ET

10.67

-0.28 -2.56 %

Financial • Insurance Brokers • Cayman Islands • NYSE

ARX Accelerant Holdings daily Stock Chart

Held by: VTI VB VBK CPAI SMLF ISCG FNCL BCFN SMLL ACSV

Index	-	P/E	-	EPS (ttm)	-	Insider Own	74.52%	Shs Outstand	114.58M	Perf Week	-8.96%
Market Cap	2.37B	Forward P/E	-	EPS next Y	-	Insider Trans	0.09%	Shs Float	56.52M	Perf Month	-30.08%
Enterprise Value	-	PEG	-	EPS next Q	0.16	Inst Own	24.11%	Short Float	4.05%	Perf Quarter	-15.32%
Income	-	P/S	-	EPS this Y	-	Inst Trans	329.76%	Short Ratio	2.05	Perf Half Y	-62.34%
Sales	-	P/B	3.50	EPS next Y	-	ROA	-	Short Interest	2.29M	Perf YTD	-34.74%
Book/sh	3.05	P/C	-	EPS next 5Y	-	ROE	-	52W High	31.18 -65.78%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	10.63 0.38%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.41% -	Gross Margin	-	Volatility	6.04% 6.21%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	21.68	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.68	EPS Q/Q	-	SMA20	-17.50%	Beta	-	Target Price	21.06
Payout	-	Debt/Eq	0.18	Sales Q/Q	-	SMA50	-27.03%	Rel Volume	1.33	Prev Close	10.95
Employees	-	LT Debt/Eq	0.18	Earnings	Nov 12 AMC	SMA200	-37.90%	Avg Volume	1.11M	Price	10.67
IPO	Jul 24, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	75.93% 5.48%	Trades		Volume	1,480,891	Change	-2.56%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-04-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform	$20
Oct-06-25	Upgrade	Goldman	Neutral → Buy	$19.50
Aug-18-25	Initiated	William Blair	Outperform
Aug-18-25	Initiated	Wells Fargo	Equal Weight	$28
Aug-18-25	Initiated	TD Cowen	Buy	$36
Aug-18-25	Initiated	RBC Capital Mkts	Outperform	$33
Aug-18-25	Initiated	Raymond James	Outperform	$33
Aug-18-25	Initiated	Piper Sandler	Overweight	$35
Aug-18-25	Initiated	Morgan Stanley	Equal-Weight	$28
Aug-18-25	Initiated	Goldman	Neutral	$30
Aug-18-25	Initiated	Citizens JMP	Mkt Perform
Aug-18-25	Initiated	BMO Capital Markets	Outperform	$34

Show Previous Ratings

Feb-09-26 08:00AM	Accelerant Announces Date of Fourth Quarter and Full Year 2025 Financial Results and Conference Call (Business Wire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-14-26 12:10PM	Will Accelerant Holdings (ARX) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Dec-12-25 05:59AM	Down Almost 50%: Analysts Expect a Rebound for These 2 Beaten-Down Stocks (TipRanks)
Dec-05-25 09:56AM	Toast upgraded, PayPal downgraded: Wall Streets top analyst calls (TipRanks)
09:53AM	Loading…
Dec-04-25 09:53AM	Toast upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly) +6.36%
Nov-28-25 06:55AM	Here's Why Accelerant Holdings (ARX) Declined in Q3 (Insider Monkey)
Nov-12-25 08:00PM	Compared to Estimates, Accelerant Holdings (ARX) Q3 Earnings: A Look at Key Metrics (Zacks) +9.21%
04:15PM	Accelerant Announces Third Quarter 2025 Results (Business Wire)
Nov-11-25 10:43AM	TeraWulf Q3 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
Nov-05-25 11:23AM	HUT 8 Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Up (Zacks)
Oct-31-25 01:39PM	Strategy Q3 Earnings Beat Estimates, Revenues Increase Y/Y (Zacks)
Oct-11-25 12:01PM	Andreessen Horowitz-Backed FurtherAI Raises $25M To Give Insurance Professionals 'Superpowers' Through Workflow Automation (Benzinga)
Oct-03-25 08:00AM	Accelerant Announces Date of Third Quarter 2025 Financial Results and Conference Call (Business Wire) +8.68%
Sep-11-25 09:00AM	Accelerant Announces Partnership With AF Specialty to Expand Risk Exchange Capacity (Business Wire)
07:49AM	Loading…
Aug-28-25 07:49AM	Stock Market Today: Stocks react to Nvidia's 'normal enough' earnings (TheStreet) -26.36%
07:00AM	Accelerant Announces Second Quarter 2025 Results (Business Wire)
Aug-18-25 01:10PM	Wall Street mixed on Accelerant; sees real platform upside, but valuation is high (Investing.com)
09:33AM	CVS Health upgraded, Occidental downgraded: Wall Street's top analyst calls (The Fly)
06:48AM	Analysts launch coverage on Accelerant Holdings, highlight growth potential (Investing.com)
Aug-13-25 04:05PM	Accelerant Announces Date of Second Quarter 2025 Financial Results and Conference Call (Business Wire)
Aug-08-25 04:00PM	IPO Stock Of The Week: New Insurance Software Leader Accelerant Eyes First Buy Point (Investor's Business Daily)
Jul-26-25 11:03AM	Accelerant Holdings (ARX) Extends IPO Rally on Strong Investor Confidence (Insider Monkey)
05:26AM	Accelerant (ARX) Soars 26% on Market Debut (Insider Monkey)
Jul-25-25 04:00PM	Accelerant Holdings Announces Closing of Upsized Initial Public Offering and Full Exercise of Over-Allotment Option (Business Wire) +12.42%
08:55AM	NYSE Content Advisory: Pre-market update + Accelerant celebrates IPO (PR Newswire)
Jul-24-25 02:27PM	Accelerant shares surge over 30% in public debut after $724 million IPO (Investing.com)
Jul-23-25 08:03PM	Accelerant Holdings Announces Pricing of Upsized Initial Public Offering (Business Wire)

Accelerant Holdings operates as a data-driven risk exchange connecting specialty insurance underwriters with risk capital partners. Through its Risk Exchange platform, the company supports members with technology, data, and operational services, earning fees for sourcing, managing, and monitoring business. Its underwriting and MGA operations focus on small-to-medium commercial clients across the US, Europe, Canada, and the UK. The company was founded by Jeff Radke, Christopher Lee-Smith and Frank O'Neill in 2018 and is headquartered in George Town, Cayman Islands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lee-Smith Christopher	Co-Founder, Head of Distrib.	Nov 19 '25	Buy	13.42	14,700	197,240	17,655,379	Dec 17 09:04 PM
Meriwether Karen Sue	Director	Dec 08 '25	Buy	14.67	542	7,951	9,752	Dec 09 04:09 PM
Gaynor Samuel	Director	Nov 19 '25	Buy	13.44	7,500	100,774	7,500	Nov 20 04:17 PM
ONeill Francis James	Co-Founder, Chief U/W Officer	Nov 18 '25	Buy	13.34	38,000	506,810	7,235,125	Nov 20 04:12 PM
Sternberg Matthew David	COO, Risk Exchange	Nov 17 '25	Buy	13.10	5,700	74,696	157,964	Nov 19 04:11 PM
RADKE JEFFREY L	Co-Founder, CEO	Nov 14 '25	Buy	13.48	74,110	999,366	28,261,939	Nov 18 08:23 AM
Schwartz Keoni Andrew	Director	Jul 25 '25	Sale	21.00	11,596,152	243,519,192	0	Jul 29 08:36 PM
Hasley Nancy	General Counsel	Jul 25 '25	Buy	21.00	500	10,500	500	Jul 29 08:22 PM

Open in Screener

DGICA

Donegal Group Inc

Feb 13 • 04:00PM ET

18.70

+0.03 0.16 %

Financial • Insurance - Property & Casualty • USA • NASD

DGICA Donegal Group Inc daily Stock Chart

Peers: PGR TRV CINF ALL HIG SIGI AFG KMPR WRB THG

| Held by: VTI IWM SMDV AVUV VXF DFAT IWN FSMD DFSV DFAS

Index	RUT	P/E	7.71	EPS (ttm)	2.43	Insider Own	53.87%	Shs Outstand	31.03M	Perf Week	-1.48%
Market Cap	674.70M	Forward P/E	9.11	EPS next Y	2.05	Insider Trans	2.44%	Shs Float	16.64M	Perf Month	-3.95%
Enterprise Value	-	PEG	0.64	EPS next Q	0.54	Inst Own	37.08%	Short Float	3.37%	Perf Quarter	-5.46%
Income	86.15M	P/S	0.68	EPS this Y	56.12%	Inst Trans	-	Short Ratio	4.95	Perf Half Y	6.80%
Sales	988.19M	P/B	1.07	EPS next Y	-6.77%	ROA	4.83%	Short Interest	0.56M	Perf YTD	-6.41%
Book/sh	17.40	P/C	-	EPS next 5Y	14.19%	ROE	15.10%	52W High	21.12 -11.46%	Perf Year	22.06%
Cash/sh	-	P/FCF	7.63	EPS past 3/5Y	22.75% -1.76%	ROIC	13.01%	52W Low	14.99 24.75%	Perf 3Y	22.78%
Dividend Est.	0.70 (3.77%)	EV/EBITDA	-	Sales past 3/5Y	6.62% 4.03%	Gross Margin	-	Volatility	2.52% 2.60%	Perf 5Y	34.92%
Dividend TTM	0.73 (3.89%)	EV/Sales	-	EPS Y/Y TTM	224.95%	Oper. Margin	10.89%	ATR (14)	0.49	Perf 10Y	28.70%
Dividend Ex-Date	Feb 03, 2026	Quick Ratio	-	Sales Y/Y TTM	0.93%	Profit Margin	8.72%	RSI (14)	44.21	Recom	3.00
Dividend Gr. 3/5Y	2.54% 3.53%	Current Ratio	0.48	EPS Q/Q	8.77%	SMA20	-0.12%	Beta	0.02	Target Price	21.00
Payout	45.13%	Debt/Eq	0.06	Sales Q/Q	-2.31%	SMA50	-4.02%	Rel Volume	0.76	Prev Close	18.67
Employees	851	LT Debt/Eq	0.06	Earnings	Feb 19 BMO	SMA200	-2.26%	Avg Volume	113.04K	Price	18.70
IPO	Apr 24, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	2.46% -5.57%	Trades		Volume	86,086	Change	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Upgrade	Janney	Neutral → Buy
Dec-20-23	Initiated	Janney	Neutral	$15
Nov-16-21	Downgrade	Keefe Bruyette	Outperform → Mkt Perform
Nov-01-17	Upgrade	Keefe Bruyette	Mkt Perform → Outperform
Oct-31-17	Upgrade	Boenning & Scattergood	Neutral → Outperform
May-25-17	Initiated	Boenning & Scattergood	Neutral
Dec-20-16	Downgrade	Keefe Bruyette	Outperform → Mkt Perform

Jan-29-26 09:00AM	Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-Year 2025 Results (GlobeNewswire)
Jan-28-26 09:10AM	How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks (Zacks)
Jan-22-26 09:10AM	3 Top Dividend Stocks to Maximize Your Retirement Income (Zacks)
Dec-18-25 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Dec-08-25 09:40AM	Are Investors Undervaluing Donegal Group (DGICA) Right Now? (Zacks)
09:40AM	Loading…
Nov-21-25 09:40AM	Should Value Investors Buy Donegal Group (DGICA) Stock? (Zacks)
Nov-10-25 09:15AM	Heritage Insurance Holdings, Inc. (HRTG) Hit a 52 Week High, Can the Run Continue? (Zacks)
Nov-05-25 09:40AM	Has Donegal Group (DGICA) Outpaced Other Finance Stocks This Year? (Zacks)
09:40AM	Are Investors Undervaluing Donegal Group (DGICA) Right Now? (Zacks)
Nov-04-25 08:12PM	Donegal Group Inc (DGICA) Q3 2025 Earnings Call Highlights: Strong Underwriting Performance ... (GuruFocus.com)
Oct-30-25 06:45AM	Donegal: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Donegal Group Inc. Announces Third Quarter and First Nine Months of 2025 Results (GlobeNewswire)
Oct-29-25 09:51AM	Donegal Group Inc (DGICA) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-20-25 09:40AM	Is Donegal Group (DGICA) Stock Undervalued Right Now? (Zacks)
Oct-16-25 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
10:30AM	Loading…
Oct-15-25 10:30AM	Heritage Insurance (HRTG) Moves 10.6% Higher: Will This Strength Last? (Zacks)
09:35AM	Progressive (PGR) Lags Q3 Earnings and Revenue Estimates (Zacks)
Oct-06-25 12:56PM	Donegal Group Inc. Announces Release Date for Third Quarter 2025 Results (GlobeNewswire)
Oct-02-25 09:40AM	Should Value Investors Buy Donegal Group (DGICA) Stock? (Zacks)
Sep-16-25 09:40AM	Are Investors Undervaluing Donegal Group (DGICA) Right Now? (Zacks)
Sep-15-25 09:15AM	United Fire Group, Inc (UFCS) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-08-25 04:59PM	Is CNA Financial (CNA) Stock Undervalued Right Now? (Zacks)
Sep-04-25 09:28AM	Best Value Stocks to Buy for September 4th (Zacks) +5.87%
Jul-25-25 07:02AM	Donegal: Q2 Earnings Snapshot (Associated Press Finance)
Jul-24-25 06:30AM	Donegal Group Inc. Announces Second Quarter and First Half 2025 Results (GlobeNewswire) -6.16%
Jul-23-25 09:59AM	Earnings To Watch: Donegal Group Inc (DGICA) Reports Q2 2025 Result (GuruFocus.com)
Jul-17-25 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Jul-02-25 03:00PM	Donegal Group Inc. Announces Release Date for Second Quarter 2025 Results (GlobeNewswire)
Apr-26-25 01:53AM	Dividend Champion, Contender, And Challenger Highlights: Week Of April 27 (Seeking Alpha)
Apr-25-25 11:09AM	Donegal Group Inc. (DGICA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30AM	Loading…
Apr-24-25 06:30AM	Donegal Group Inc. Announces First Quarter 2025 Results (GlobeNewswire) +5.39%
Apr-19-25 01:25AM	Dividend Champion, Contender, And Challenger Highlights: Week Of April 20 (Seeking Alpha)
Apr-17-25 10:00AM	Donegal Group Inc. Announces Increase in Quarterly Dividend (GlobeNewswire)
Apr-02-25 10:00AM	Donegal Group Inc. Announces Release Date for First Quarter 2025 Results (GlobeNewswire)
Mar-23-25 07:41AM	Is Donegal Group (DGICA) The Stock With The Most Insider Sales In The Last Quarter? (InsiderMonkey)
Feb-20-25 06:30AM	Donegal Group Inc. Announces Fourth Quarter and Full Year 2024 Results (GlobeNewswire)
Feb-03-25 01:00PM	Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-Year 2024 Results (GlobeNewswire)
Dec-19-24 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Oct-24-24 06:30AM	Donegal Group Inc. Announces Third Quarter and First Nine Months of 2024 Results (GlobeNewswire) +8.60%
Oct-17-24 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Oct-01-24 03:00PM	Donegal Group Inc. Announces Release Date for Third Quarter 2024 Results (GlobeNewswire)
Sep-25-24 08:05AM	Genpact and Donegal Insurance Group to Elevate Commercial Lines Underwriting Efficiency with Guidewire Solutions (PR Newswire)
Jul-25-24 06:30AM	Donegal Group Inc. Announces Second Quarter and First Half 2024 Results (GlobeNewswire) +5.63%
Jul-18-24 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Jul-01-24 09:00AM	Donegal Group Inc. Announces Release Date for Second Quarter 2024 Results (GlobeNewswire)
May-02-24 01:16PM	AM Best Affirms Credit Ratings of Donegal Insurance Group Members and Donegal Group Inc. (Business Wire)
Apr-25-24 07:45AM	Donegal Group (DGICA) Lags Q1 Earnings Estimates (Zacks)
06:30AM	Donegal Group Inc. Announces First Quarter 2024 Results (GlobeNewswire)
Apr-18-24 10:20AM	Donegal Group Inc. Announces Increase in Quarterly Dividend (GlobeNewswire)
Apr-02-24 01:00PM	Donegal Group Inc. Announces Release Date for First Quarter 2024 Results (GlobeNewswire)
Feb-22-24 06:30AM	Donegal Group Inc. Announces Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Feb-01-24 08:30AM	Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-Year 2023 Results (GlobeNewswire)
Jan-02-24 09:30AM	Donegal Insurance Group Names Two to Posts of Chief Operating Officer, SVP of Field Operations & National Accounts (GlobeNewswire)
Dec-21-23 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Oct-28-23 12:44PM	Donegal Group Inc. (NASDAQ:DGICA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-26-23 06:30AM	Donegal Group Inc. Announces Third Quarter and First Nine Months of 2023 Results (GlobeNewswire)
Oct-19-23 03:30PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Sep-27-23 08:00AM	Donegal Group Inc. Announces Release Date for Third Quarter 2023 Results (GlobeNewswire)
Jul-27-23 06:30AM	Donegal Group Inc. Announces Second Quarter and First Half 2023 Results (GlobeNewswire)
Jul-20-23 04:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Jun-27-23 11:00AM	Donegal Group Inc. Announces Release Date for Second Quarter 2023 Results (GlobeNewswire)
Apr-27-23 06:30AM	Donegal Group Inc. Announces First Quarter 2023 Results (GlobeNewswire)
Apr-20-23 10:15AM	Donegal Group Inc. Announces Increase in Quarterly Dividend (GlobeNewswire)
Mar-28-23 03:00PM	Donegal Group Inc. Announces Release Date for First Quarter 2023 Results (GlobeNewswire)
Feb-23-23 06:30AM	Donegal Group Inc. Announces Fourth Quarter and Full Year 2022 Results (GlobeNewswire)
Jan-23-23 01:00PM	Donegal Group Inc. Announces Release Date for Fourth Quarter and Full-Year 2022 Results (GlobeNewswire)
Dec-15-22 03:58PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Nov-21-22 08:14AM	One Donegal Group Inc. (NASDAQ:DGIC.A) insider upped their stake by 5.3% in the previous year (Simply Wall St.)
Oct-27-22 06:30AM	Donegal Group Inc. Announces Third Quarter and First Nine Months of 2022 Results (GlobeNewswire)
Oct-25-22 07:34AM	Donegal Group Inc.'s (NASDAQ:DGIC.A) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? (Simply Wall St.)
Oct-20-22 02:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Sep-28-22 01:00PM	Donegal Group Inc. Announces Release Date for Third Quarter 2022 Results (GlobeNewswire)
Aug-22-22 06:12AM	Investors in Donegal Group (NASDAQ:DGIC.A) have made a return of 27% over the past three years (Simply Wall St.)
Jul-28-22 06:30AM	Donegal Group Inc. Announces Second Quarter and First Half 2022 Results (GlobeNewswire) -10.23%
Jul-21-22 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Jul-04-22 12:06PM	What Type Of Shareholders Own The Most Number of Donegal Group Inc. (NASDAQ:DGIC.A) Shares? (Simply Wall St.)
Jun-29-22 08:00AM	Donegal Insurance Group Taps David Sponic to Lead Personal Lines Division (GlobeNewswire)
Jun-28-22 08:30AM	Donegal Group Inc. Announces Release Date for Second Quarter 2022 Results (GlobeNewswire)
Jun-05-22 10:25AM	Quite a few insiders invested in Donegal Group Inc. (NASDAQ:DGIC.A) last year which is positive news for shareholders (Simply Wall St.)
May-18-22 06:31AM	Is Donegal Group Inc.'s (NASDAQ:DGIC.A) Recent Stock Performance Influenced By Its Fundamentals In Any Way? (Simply Wall St.)
Apr-28-22 07:55AM	Donegal Group (DGICA) Q1 Earnings Beat Estimates (Zacks)
06:30AM	Donegal Group Inc. Announces First Quarter 2022 Results (GlobeNewswire)
Apr-25-22 06:04AM	Donegal Group's (NASDAQ:DGIC.A) Dividend Will Be Increased To US$0.17 (Simply Wall St.)
Apr-21-22 03:01PM	Earnings Preview: Donegal Group (DGICA) Q1 Earnings Expected to Decline (Zacks)
10:00AM	Donegal Group Inc. Announces Increase in Quarterly Dividend (GlobeNewswire)
Apr-18-22 09:16AM	Donegal Insurance Group Names Hudnall as New SVP of Commercial Lines (GlobeNewswire)
Mar-31-22 04:30PM	Donegal Group Inc. Announces Release Date for First Quarter 2022 Results (GlobeNewswire)
09:47AM	AM Best Affirms Credit Ratings for Members of Donegal Insurance Group and Donegal Group Inc. (Business Wire)
Mar-15-22 07:37AM	Shareholders in Donegal Group (NASDAQ:DGIC.A) are in the red if they invested five years ago (Simply Wall St.)
Feb-17-22 05:25PM	Donegal Group (DGICA) Lags Q4 Earnings and Revenue Estimates (Zacks)
04:05PM	Donegal Group Inc. Announces 2021 Fourth Quarter and Full Year Results (GlobeNewswire)
Feb-10-22 03:01PM	Analysts Estimate Donegal Group (DGICA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jan-25-22 06:28AM	Do Institutions Own Donegal Group Inc. (NASDAQ:DGIC.A) Shares? (Simply Wall St.)
Jan-20-22 03:30PM	Donegal Group Inc. Announces Fourth Quarter 2021 Conference Call and Webcast (GlobeNewswire)
Dec-17-21 05:54AM	Multiple insiders bought Donegal Group Inc. (NASDAQ:DGIC.A) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Dec-16-21 03:00PM	Donegal Group Inc. Announces Quarterly Dividend (GlobeNewswire)
Oct-28-21 08:31PM	Donegal Group, inc (DGICA) Q3 2021 Earnings Call Transcript (Motley Fool)
Oct-27-21 05:45PM	Donegal Group (DGICA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Donegal Group Inc. Announces Third Quarter and First Nine Months of 2021 Results (GlobeNewswire)
Oct-25-21 06:44AM	Why You Might Be Interested In Donegal Group Inc. (NASDAQ:DGIC.A) For Its Upcoming Dividend (Simply Wall St.)

Donegal Group, Inc. is an insurance holding company, which engages in the provision of property and casualty insurance to businesses and individuals. It operates through the following segments: Investment Function, Personal Lines of Insurance, and Commercial Lines of Insurance. The Investment Function segment covers investment activities. The Personal Lines of Insurance segment consists of homeowners and private passenger automobile policies. The Commercial Lines of Insurance segment includes commercial automobile, commercial multi-peril, and workers compensation policies. The company was founded on August 26, 1986 and is headquartered in Marietta, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAWEL DAVID BENJAMIN	SVP & CHIEF ACCOUNTING OFFICER	Dec 11 '25	Option Exercise	14.39	674	9,699	22,010	Dec 15 08:28 AM
BAWEL DAVID BENJAMIN	SVP & CHIEF ACCOUNTING OFFICER	Dec 11 '25	Sale	20.39	674	13,745	21,336	Dec 15 08:28 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Dec 10 '25	Buy	20.05	22,819	457,473	13,913,704	Dec 12 01:57 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Dec 09 '25	Buy	19.81	28,000	554,719	13,890,885	Dec 10 09:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Dec 08 '25	Buy	19.53	27,524	537,643	13,862,885	Dec 10 09:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Dec 01 '25	Buy	20.20	15,000	303,075	13,820,361	Dec 03 09:57 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Dec 02 '25	Buy	19.95	15,000	299,184	13,835,361	Dec 03 09:57 AM
ALTSHULER KRISTI SPENCER	Sr. Vice President	Dec 01 '25	Option Exercise	14.39	12,000	172,680	12,000	Dec 03 09:54 AM
ALTSHULER KRISTI SPENCER	Sr. Vice President	Dec 01 '25	Sale	20.25	12,000	243,016	0	Dec 03 09:54 AM
ALTSHULER KRISTI SPENCER	Officer	Dec 01 '25	Proposed Sale	20.20	12,000	242,400		Dec 01 02:05 PM
BAWEL DAVID BENJAMIN	Officer	Dec 01 '25	Proposed Sale	20.39	9,000	183,510		Dec 01 01:13 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 26 '25	Buy	20.25	5,000	101,270	13,805,361	Dec 01 08:29 AM
KRAFT KEVIN MICHAEL SR	Director	Nov 25 '25	Option Exercise	14.43	4,500	64,935	17,936	Nov 26 09:21 AM
KRAFT KEVIN MICHAEL SR	Director	Nov 25 '25	Sale	20.02	4,500	90,081	13,436	Nov 26 09:21 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 25 '25	Buy	20.18	8,000	161,417	13,800,361	Nov 26 09:12 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 24 '25	Buy	19.77	8,000	158,130	13,792,361	Nov 26 09:12 AM
KRAFT KEVIN MICHAEL SR	Director	Nov 25 '25	Proposed Sale	20.06	4,500	90,270		Nov 25 12:40 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 21 '25	Buy	17.86	51,404	917,948	13,784,361	Nov 24 08:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 20 '25	Buy	19.49	8,000	155,898	13,776,361	Nov 24 08:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 19 '25	Buy	19.62	7,587	148,845	13,768,361	Nov 20 09:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 18 '25	Buy	19.84	7,104	140,953	13,760,774	Nov 20 09:18 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 14 '25	Buy	19.92	8,000	159,357	13,745,670	Nov 18 08:39 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 17 '25	Buy	19.91	8,000	159,262	13,753,670	Nov 18 08:39 AM
SZADY ANNETTE BROOKENS	Director	Nov 13 '25	Option Exercise	14.43	4,500	64,935	7,000	Nov 14 09:53 AM
SZADY ANNETTE BROOKENS	Director	Nov 13 '25	Sale	19.73	4,500	88,767	2,500	Nov 14 09:53 AM
HECKER RICK JOSEPH	SVP & GENERAL COUNSEL	Nov 13 '25	Option Exercise	14.43	900	12,987	900	Nov 14 09:48 AM
HECKER RICK JOSEPH	SVP & GENERAL COUNSEL	Nov 13 '25	Sale	19.74	900	17,762	0	Nov 14 09:48 AM
WAGNER DANIEL J	Sr. VP & Treasurer	Nov 13 '25	Option Exercise	15.05	9,617	144,728	105,001	Nov 14 09:43 AM
WAGNER DANIEL J	Sr. VP & Treasurer	Nov 12 '25	Option Exercise	14.03	8,383	117,592	103,767	Nov 14 09:43 AM
WAGNER DANIEL J	Sr. VP & Treasurer	Nov 13 '25	Sale	19.76	9,617	190,013	95,384	Nov 14 09:43 AM
WAGNER DANIEL J	Sr. VP & Treasurer	Nov 12 '25	Sale	19.77	8,383	165,698	95,384	Nov 14 09:43 AM
Moore Sewell Trezevant Jr	Director	Nov 13 '25	Option Exercise	14.43	4,500	64,935	30,655	Nov 14 09:35 AM
Moore Sewell Trezevant Jr	Director	Nov 13 '25	Sale	19.70	4,500	88,671	26,155	Nov 14 09:35 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 13 '25	Buy	19.53	29,000	566,300	13,737,670	Nov 14 09:26 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 12 '25	Buy	19.74	6,794	134,107	13,708,670	Nov 14 09:26 AM
SZADY ANNETTE BROOKENS	Director	Nov 13 '25	Proposed Sale	19.77	4,500	88,965		Nov 13 10:31 AM
Moore Sewell Trezevant Jr	Director	Nov 12 '25	Proposed Sale	19.71	4,500	88,695		Nov 12 03:02 PM
WAGNER DANIEL J	Sr. VP & Treasurer	Nov 11 '25	Proposed Sale	19.75	18,000	355,500		Nov 12 08:53 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 10 '25	Buy	19.36	8,000	154,907	13,694,579	Nov 12 08:19 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 07 '25	Buy	19.21	8,000	153,650	13,686,579	Nov 12 08:19 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 11 '25	Buy	19.66	7,297	143,460	13,701,876	Nov 12 08:19 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 06 '25	Buy	19.13	8,000	153,034	13,678,579	Nov 07 08:51 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 05 '25	Buy	19.11	8,000	152,847	13,670,579	Nov 07 08:51 AM
MAHAN JON MARSHALL	Director	Nov 05 '25	Option Exercise	14.43	4,500	64,935	13,988	Nov 05 05:52 PM
MAHAN JON MARSHALL	Director	Nov 05 '25	Sale	19.07	4,500	85,810	9,488	Nov 05 05:52 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Nov 04 '25	Buy	18.71	8,000	149,704	13,662,579	Nov 05 05:04 PM
MAHAN JON MARSHALL	Director	Nov 05 '25	Proposed Sale	19.09	4,500	85,900		Nov 05 01:10 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 12 '25	Buy	19.53	20,000	390,654	13,654,579	Sep 15 08:29 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 10 '25	Buy	18.99	20,000	379,896	13,618,006	Sep 12 09:08 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 11 '25	Buy	19.45	16,573	322,424	13,634,579	Sep 12 09:08 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 09 '25	Buy	19.24	19,352	372,292	13,598,006	Sep 10 08:53 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 08 '25	Buy	19.10	19,025	363,417	13,578,654	Sep 10 08:53 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 04 '25	Buy	19.22	19,212	369,339	13,559,629	Sep 08 08:59 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 03 '25	Buy	18.37	20,000	367,356	13,540,417	Sep 04 08:14 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Sep 02 '25	Buy	18.27	19,440	355,136	13,520,417	Sep 04 08:14 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Aug 29 '25	Buy	17.84	20,000	356,724	13,500,977	Sep 02 10:27 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Aug 28 '25	Buy	17.61	8,032	141,417	13,480,977	Sep 02 10:27 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Aug 26 '25	Buy	17.45	15,815	275,951	13,457,436	Aug 28 09:22 AM
DONEGAL MUTUAL INSURANCE CO	10% Owner	Aug 27 '25	Buy	17.49	15,509	271,325	13,472,945	Aug 28 09:22 AM
KING DAVID CHARLES	Director	Aug 27 '25	Option Exercise	14.43	4,500	64,935	7,000	Aug 28 09:17 AM
KING DAVID CHARLES	Director	Aug 27 '25	Sale	17.51	4,500	78,782	2,500	Aug 28 09:17 AM
KING DAVID CHARLES	Director	Aug 27 '25	Proposed Sale	17.50	4,500	78,750		Aug 27 05:06 PM
HESS JACK LEE	Director	Jul 29 '25	Option Exercise	14.57	4,500	65,580	120,920	Jul 30 10:42 AM
VIOZZI VINCENT ANTHONY	Sr. VP & Chief Inv Officer	May 27 '25	Option Exercise	14.39	18,000	259,020	27,316	May 28 08:58 AM
VIOZZI VINCENT ANTHONY	Sr. VP & Chief Inv Officer	May 27 '25	Sale	20.24	19,173	388,120	8,143	May 28 08:58 AM
VIOZZI VINCENT ANTHONY	Officer	May 27 '25	Proposed Sale	20.36	18,000	366,480		May 27 12:40 PM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 23 '25	Option Exercise	14.39	8,696	125,135	10,191	May 27 10:13 AM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 23 '25	Sale	19.78	8,696	171,998	1,495	May 27 10:13 AM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 23 '25	Option Exercise	14.39	8,696	125,135	10,191	May 27 10:10 AM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 23 '25	Sale	19.78	8,696	171,998	1,495	May 27 10:10 AM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 21 '25	Option Exercise	14.39	304	4,375	1,799	May 22 04:57 PM
DELAMATER WILLIAM DANIEL	EVP & Chief Oper Officer	May 21 '25	Sale	20.50	304	6,232	1,495	May 22 04:57 PM
ALTSHULER KRISTI SPENCER	Officer	May 21 '25	Proposed Sale	20.61	12,000	247,320		May 21 10:03 AM
DELAMATER WILLIAM DANIEL	Officer	May 21 '25	Proposed Sale	20.61	9,000	185,490		May 21 10:01 AM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 19 '25	Option Exercise	14.02	18,000	252,300	18,950	May 20 08:23 AM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 19 '25	Sale	20.67	18,000	371,988	950	May 20 08:23 AM
FOLMAR WILLIAM ALBERT	Officer	May 19 '25	Proposed Sale	20.60	18,000	370,800		May 19 10:57 AM
PANDEY SANJAY	Sr. VP & Chief Info Officer	May 15 '25	Option Exercise	14.39	12,982	186,811	20,431	May 19 09:11 AM
PANDEY SANJAY	Sr. VP & Chief Info Officer	May 15 '25	Sale	20.27	12,982	263,171	7,449	May 19 09:11 AM
Huber Barry C	Director	May 15 '25	Option Exercise	14.41	9,000	129,690	24,367	May 15 03:30 PM
Huber Barry C	Director	May 15 '25	Sale	20.23	9,000	182,034	15,367	May 15 03:30 PM
SPONIC DAVID WAYNE	Senior Vice President	May 15 '25	Option Exercise	14.39	11,582	166,665	13,588	May 15 03:27 PM
SPONIC DAVID WAYNE	Senior Vice President	May 15 '25	Sale	20.04	11,582	232,103	2,006	May 15 03:27 PM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 15 '25	Option Exercise	14.39	1,150	16,548	2,100	May 15 03:25 PM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 15 '25	Sale	19.89	1,150	22,868	950	May 15 03:25 PM
HAY JEFFERY TIM	Senior Vice President	May 15 '25	Option Exercise	14.07	9,572	134,678	15,684	May 15 03:22 PM
HAY JEFFERY TIM	Senior Vice President	May 15 '25	Sale	20.01	9,572	191,574	6,112	May 15 03:22 PM
Huber Barry C	Director	May 15 '25	Proposed Sale	20.10	9,000	180,900		May 15 03:01 PM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 13 '25	Option Exercise	14.39	12,576	180,969	13,526	May 15 11:22 AM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 14 '25	Option Exercise	14.39	4,274	61,503	5,224	May 15 11:22 AM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 13 '25	Sale	19.90	12,576	250,288	950	May 15 11:22 AM
FOLMAR WILLIAM ALBERT	Sr. Vice President	May 14 '25	Sale	19.82	4,274	84,694	950	May 15 11:22 AM
HAY JEFFERY TIM	Senior Vice President	May 13 '25	Option Exercise	14.07	346	4,868	6,458	May 15 11:14 AM
HAY JEFFERY TIM	Senior Vice President	May 13 '25	Sale	20.01	346	6,923	6,112	May 15 11:14 AM
SPONIC DAVID WAYNE	Senior Vice President	May 13 '25	Option Exercise	14.39	418	6,015	2,424	May 15 11:11 AM
SPONIC DAVID WAYNE	Senior Vice President	May 13 '25	Sale	20.01	418	8,363	2,006	May 15 11:11 AM
FOLMAR WILLIAM ALBERT	Officer	May 13 '25	Proposed Sale	19.81	18,000	356,580		May 13 12:23 PM
DONEGAL MUTUAL INSURANCE CO	10% Owner	May 12 '25	Buy	19.83	71,000	1,408,214	13,441,621	May 13 10:05 AM
MILLER JEFFREY DEAN	EVP & Chief Financial Officer	May 12 '25	Option Exercise	14.43	24,000	346,320	47,980	May 13 10:02 AM
MILLER JEFFREY DEAN	EVP & Chief Financial Officer	May 12 '25	Sale	19.83	24,000	476,016	23,980	May 13 10:02 AM

Open in Screener

SUNC

SunocoCorp LLC

Feb 13 • 04:00PM ET

55.12

+0.40 0.73 %

Energy • Oil & Gas Midstream • USA • NYSE

Held by: ESML DES UMI IDEV DFIS DFIC IXUS AVUS FENY PIPE

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.03%	Shs Outstand	42.95M	Perf Week	2.34%
Market Cap	2.37B	Forward P/E	-	EPS next Y	-	Insider Trans	34.93%	Shs Float	42.94M	Perf Month	1.64%
Enterprise Value	-	PEG	-	EPS next Q	1.90	Inst Own	48.23%	Short Float	3.29%	Perf Quarter	13.91%
Income	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	2.31	Perf Half Y	-
Sales	-	P/B	-	EPS next Y	-	ROA	-	Short Interest	1.41M	Perf YTD	11.85%
Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W High	56.26 -2.03%	Perf Year	-
Cash/sh	-	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	47.00 17.28%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	2.16% 2.32%	Perf 5Y	-
Dividend TTM	0.93 (1.69%)	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.26	Perf 10Y	-
Dividend Ex-Date	Feb 06, 2026	Quick Ratio	-	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	64.84	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	-	EPS Q/Q	-29.22%	SMA20	1.94%	Beta	-	Target Price	65.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	5.91%	Rel Volume	0.33	Prev Close	54.72
Employees	-	LT Debt/Eq	-	Earnings	Feb 17 BMO	SMA200	6.58%	Avg Volume	611.05K	Price	55.12
IPO	Nov 06, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	-4.98% -	Trades		Volume	201,990	Change	0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Upgrade	Raymond James	Outperform → Strong Buy	$70
Nov-17-25	Initiated	Raymond James	Outperform
Nov-11-25	Initiated	Citigroup	Buy	$65

Jan-27-26 04:24PM	Sunoco LP and SunocoCorp LLC Announce Quarterly Distributions (Business Wire)
Jan-13-26 11:02AM	Sunoco LP and SunocoCorp LLC Announce Fourth Quarter and Full Year 2025 Earnings Release and Call Timing (Business Wire)
Jan-06-26 07:02AM	Sunoco LP Announces 2026 Guidance (Business Wire)
Nov-12-25 09:35AM	DraftKings downgraded, Instacart upgraded: Wall Streets top analyst calls (TipRanks)
Nov-11-25 09:32AM	DraftKings downgraded, Instacart upgraded: Wall Street's top analyst calls (The Fly)
09:06AM	Loading…
09:06AM	Here are Tuesdays Top Wall Street Analyst Research Calls: Coreweave, Instacart, Qorvo, Robinhood Markets, Skyworks Solutions, Viasat and More (24/7 Wall St.)
Nov-07-25 02:12PM	LNG Export Demand Driving Natural Gas to Highs: 5 Strong Buy Dividend Leaders (24/7 Wall St.)
Nov-06-25 12:02PM	Sunoco LP (SUN) Q3 2025 Earnings Call Highlights: Record EBITDA and Strategic Acquisition ... (GuruFocus.com)

SunocoCorp LLC engages in operating crude oil pipelines and terminals. The company was founded on June 6, 2000 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jennings Michael	Director	Nov 26 '25	Buy	52.00	1,000	52,000	8,590	Dec 01 08:00 AM
Jennings Michael	Director	Nov 17 '25	Buy	49.68	3,000	149,037	7,590	Nov 18 09:14 AM

Open in Screener

BHVN

Biohaven Ltd

Feb 13 • 04:00PM ET

11.36

-0.14 -1.22 %

Healthcare • Biotechnology • USA • NYSE

Peers: VRTX AMGN REGN GILD BMRN NBIX ALNY INCY SRPT EXEL

| Held by: XBI IWM VXF PINK IBB IWO SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-7.60	Insider Own	11.89%	Shs Outstand	145.19M	Perf Week	-2.07%
Market Cap	1.65B	Forward P/E	-	EPS next Y	-3.11	Insider Trans	34.38%	Shs Float	127.92M	Perf Month	-2.91%
Enterprise Value	1.70B	PEG	-	EPS next Q	-1.19	Inst Own	74.82%	Short Float	16.19%	Perf Quarter	42.89%
Income	-780.11M	P/S	-	EPS this Y	28.78%	Inst Trans	21.62%	Short Ratio	6.29	Perf Half Y	-20.17%
Sales	0.00M	P/B	-	EPS next Y	53.01%	ROA	-169.65%	Short Interest	20.71M	Perf YTD	0.62%
Book/sh	-0.16	P/C	6.32	EPS next 5Y	38.33%	ROE	-522.08%	52W High	42.82 -73.47%	Perf Year	-72.82%
Cash/sh	1.80	P/FCF	-	EPS past 3/5Y	-40.84% -49.78%	ROIC	-267.62%	52W Low	7.48 51.87%	Perf 3Y	-36.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.75% 7.36%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	18.76%	Oper. Margin	-	ATR (14)	0.92	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.86	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	46.65	Recom	1.69
Dividend Gr. 3/5Y	- -	Current Ratio	2.86	EPS Q/Q	3.50%	SMA20	-6.73%	Beta	3.52	Target Price	20.67
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-0.45%	Rel Volume	0.52	Prev Close	11.50
Employees	256	LT Debt/Eq	-	Earnings	Nov 10 BMO	SMA200	-18.41%	Avg Volume	3.29M	Price	11.36
IPO	May 04, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	13.73% -100.00%	Trades		Volume	1,724,229	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-26	Initiated	Goldman	Buy	$23
Jan-21-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$22
Dec-03-25	Downgrade	H.C. Wainwright	Buy → Neutral	$11
Nov-26-25	Downgrade	UBS	Buy → Neutral	$11
Nov-06-25	Downgrade	Bernstein	Outperform → Mkt Perform	$9
Nov-05-25	Downgrade	BofA Securities	Buy → Neutral	$10
Sep-17-25	Initiated	Citigroup	Buy	$28
Sep-03-25	Initiated	Raymond James	Strong Buy	$75
May-19-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$21
Feb-11-25	Initiated	Deutsche Bank	Buy	$65
Sep-16-24	Initiated	Jefferies	Buy	$57
Sep-04-24	Initiated	Bernstein	Outperform	$55
Jul-24-24	Initiated	Morgan Stanley	Overweight	$58
Feb-16-24	Initiated	RBC Capital Mkts	Outperform	$62
Feb-06-24	Initiated	UBS	Buy	$59
Dec-22-23	Initiated	H.C. Wainwright	Buy	$50
Dec-08-23	Initiated	Robert W. Baird	Outperform	$58
Jan-24-23	Initiated	SVB Securities	Outperform	$24
Jan-04-23	Initiated	JP Morgan	Overweight	$23
Dec-02-22	Initiated	BTIG Research	Buy	$24

Show Previous Ratings

Feb-10-26 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-09-26 09:55AM	Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect? (Zacks) +10.17%
Feb-06-26 08:07AM	Here Are Fridays Top Wall Street Analyst Research Calls: Amazon.com, Caterpillar, Estee Lauder, JPMorgan, Norfolk Southern, Roku, Snap, Vistra, and More (24/7 Wall St.) +7.81%
Jan-22-26 09:40AM	Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? (Zacks) +6.92%
Jan-14-26 09:48PM	Biohaven (BHVN) Stock Is Trending Overnight - Here's What You Should Know (Benzinga) +6.65%
11:15AM	Loading…
Jan-12-26 11:15AM	Biohaven Highlights Portfolio Progress, Positive Early Patient Data from Priority Degrader Programs and Anticipated Milestones at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +6.57%
Jan-07-26 07:00AM	Biohaven to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026 (PR Newswire) +22.04%
Dec-26-25 02:56PM	Christmas Week Brings S&P 500 Records, Tech Volatility (Schaeffer's Research)
02:14PM	These Stocks Are Moving the Most Today: Nvidia, Apple, Tesla, Coupang, Micron, Lam Research, Newmont, Moderna, and More (Barrons.com)
10:25AM	Biohaven Stock Gaps Lower on Failed Phase 2 Drug Trial (Schaeffer's Research)
08:18AM	Biohaven sinks on disappointing trial and other early movers (MarketWatch)
07:39AM	These Stocks Are Moving the Most Today: Nvidia, Micron, Nike, Tesla, Biohaven, Coupang, and More (Barrons.com)
06:07AM	S&P Futures Muted in Thin Post-Christmas Trade (Barchart)
04:27AM	Stock Market Today: Dow, S&P 500 set to hover near fresh records in thin holiday trading; silver, gold and copper rally continue, industrial metals also climb (MarketWatch)
Dec-24-25 01:00PM	Biohaven Provides Update From Phase 2 Proof-of-Concept Study with BHV-7000 in Major Depressive Disorder (PR Newswire)
09:55AM	Loading…
09:55AM	Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know (Zacks)
Dec-19-25 12:00PM	Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know (Zacks)
Dec-11-25 07:00AM	Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (PR Newswire) +7.92%
Dec-04-25 09:55AM	How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% (Zacks) +5.37%
Dec-03-25 09:15AM	Here Are Wednesdays Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendys and More (24/7 Wall St.)
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly)
Nov-24-25 08:40AM	Jim Cramer on Biohaven: "The Stock Seems Very Low to Me" (Insider Monkey)
Nov-20-25 12:37PM	Biohaven Insiders Bet $33 Million on a Turnaround (MarketBeat)
Nov-18-25 09:45AM	Carl Icahn Makes Another Huge Insider Purchase (24/7 Wall St.) +14.27%
Nov-16-25 10:13PM	William Blair Maintains Bullish Stance on Biohaven (BHVN), Sees Robust Operational Growth (Insider Monkey)
Nov-13-25 04:05PM	Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M (PR Newswire)
Nov-12-25 07:15AM	Biohaven Announces Pricing of $175 Million Public Offering of Common Shares (PR Newswire) -6.69%
Nov-11-25 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire) +9.37%
Nov-10-25 06:58AM	Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.69%
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily) -40.22%
06:59AM	Loading…
06:59AM	Knocked back by the FDA, Biohaven turns to major cost cuts (BioPharma Dive)
Nov-04-25 08:06PM	FDA Issues Complete Response Letter for Biohaven's VYGLXIA (troriluzole) New Drug Application for Spinocerebellar Ataxia (PR Newswire) -6.06%
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly) +8.97%
Sep-14-25 05:30AM	Biotech stocks: Who wins and who loses if RFK, Jr. goes (Investing.com)
Sep-09-25 04:14PM	Shareholders of Biohaven Ltd. (BHVN): Protect Your Rights Before September 12, 2025 - Contact Levi & Korsinsky (Newsfile)
Sep-03-25 05:48PM	Biohaven Ltd. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BHVN (Business Wire)
12:01PM	Biohavens rare disease drug is ready to ship on Day 1 following FDA approval (BioPharma Dive)
Aug-22-25 06:18PM	Why Biohaven Stock Zoomed More Than 6% Higher Today (Motley Fool) +6.34%
04:15PM	Biohaven Surges After FDA Cancels Key Meeting. But Is It Good News? (Investor's Business Daily)
09:14AM	Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting (Benzinga)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-20-25 10:40AM	RBC says PTC Therapeutics CRL may signal difficulty for Biohaven (TipRanks)
Aug-18-25 04:55PM	Investors Urged to Contact Levi & Korsinsky for Information Before September 12, 2025 - Biohaven Ltd. (BHVN) (Newsfile)
Aug-17-25 11:41PM	Leerink Lowers Biohaven (BHVN) PT to $50 Following Q2 Report, Acknowledging Positive Pipeline Progress (Insider Monkey)
Aug-11-25 07:00AM	Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -9.02%
Aug-08-25 04:23PM	Biohaven Ltd. (BHVN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before September 12, 2025 (Newsfile)
Jul-29-25 08:45AM	Shareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights - BHVN (PR Newswire)
Jul-21-25 04:37PM	Did You Lose Money on Biohaven Ltd. (BHVN)? Levi & Korsinsky Urges Investors to Act Before September 12, 2025 (Newsfile)
Jul-15-25 08:59AM	Biohaven, Bexorg Partner to Accelerate CNS Drug Discovery Using Novel Whole-Brain Platform (Insider Monkey) -6.55%
Jun-10-25 02:00PM	Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development (GlobeNewswire)
May-29-25 07:01AM	Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor (PR Newswire)
12:16AM	Biohaven Ltd. (BHVN)'s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy (Insider Monkey)
May-28-25 03:00PM	Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN) (PR Newswire)
07:30AM	Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors (PR Newswire)
May-15-25 06:03PM	Why Biohaven Stock Dove by Nearly 20% on Thursday (Motley Fool) -19.53%
02:06PM	Biohaven Plunges On A Surprise FDA Twist For Its Rare-Disease Drug (Investor's Business Daily)
01:22PM	Why Is Biohaven Stock Falling On Thursday? (Benzinga)
May-14-25 06:43PM	FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia (PR Newswire)
May-12-25 04:05PM	Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments (PR Newswire) -5.11%
May-09-25 08:49AM	Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts (Insider Monkey)
May-05-25 08:00AM	Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (Seeking Alpha)
Apr-28-25 01:16PM	Why BioHaven Stock Is Soaring Today (Motley Fool) +9.58%
07:30AM	Biohaven Announces Investment up to $600 Million by Oberland Capital (PR Newswire)
Apr-26-25 12:10PM	Biohaven share price undervaluing pipeline potential, says RBC Capital (TipRanks)
Apr-25-25 05:10PM	Why Biohaven Stock Plummeted by More Than 15% Today (Motley Fool) -15.21% +9.58%
Apr-23-25 06:12PM	Jim Cramer Says Biohaven (BHVN) Is "Too Cheap" and He's a Buyer at $21 (Insider Monkey) +9.24%
01:02PM	Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-17-25 11:07AM	Scholar Rock: Apitegromab Approval And Obesity Shot Make For Rating Upgrade (Seeking Alpha) +9.05%
Apr-05-25 09:00AM	Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting (PR Newswire)
Apr-03-25 09:30AM	Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March (Motley Fool) -13.22%
Apr-01-25 11:55AM	American Century Companies boosts stake in Biohaven, ETF Daily News says (TipRanks) -5.99%
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-09-25 04:37PM	Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 (Insider Monkey)
Mar-07-25 10:31AM	Biohaven price target lowered to $63 from $69 at Morgan Stanley (TipRanks)
Mar-04-25 04:50PM	Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity (Investor's Business Daily)
Mar-03-25 07:31AM	Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 (PR Newswire) -13.77%
07:30AM	Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
Feb-11-25 06:42PM	Why Biohaven Stock Triumphed on Tuesday (Motley Fool) +11.19%
04:11PM	Biohaven Just Hurdled An FDA Setback And Its Moving Lines (Investor's Business Daily)
01:29PM	Why Biohaven (BHVN) Stock Is Rallying Today (Insider Monkey)
07:30AM	Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia (PR Newswire)
Jan-24-25 05:48PM	Pfizer to Pay $60 Million in Kickback, False Claims Settlement (The Wall Street Journal)
Jan-13-25 11:15AM	Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy (PR Newswire)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 05:54PM	Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-17-24 02:23PM	Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval (Benzinga) -5.60%
06:06AM	Is Biohaven Ltd. (BHVN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-16-24 07:30AM	Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates (PR Newswire) +7.72%
Dec-06-24 07:30AM	Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting (PR Newswire)
Nov-25-24 11:51AM	Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study (Benzinga)
07:30AM	Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity (PR Newswire)
Nov-12-24 04:05PM	Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments (PR Newswire)
Oct-07-24 04:13PM	Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily) +10.75%
09:41AM	Scholar Rock Catapults By Triple Digits On Final-Phase Win In Spinal Muscular Atrophy (Investor's Business Daily)
Oct-02-24 04:05PM	Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
Oct-01-24 06:00AM	Biohaven Announces Pricing of $250 Million Public Offering of Common Shares (PR Newswire)
Sep-30-24 04:05PM	Biohaven Announces Proposed Public Offering of Common Shares (PR Newswire)
07:30AM	Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine (PR Newswire)
Sep-23-24 07:30AM	Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) (PR Newswire) +13.74%

Biohaven Ltd. is a global clinical stage biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for people with neurological and neuropsychiatric diseases. The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gentile Kimberly	SVP, Clinical Operations	Jan 05 '26	Option Exercise	0.00	3,750	0	101,513	Jan 07 09:34 PM
Buten Matthew	Chief Financial Officer	Jan 05 '26	Option Exercise	0.00	4,250	0	198,246	Jan 07 09:33 PM
Coric Vlad	Chief Executive Officer	Jan 05 '26	Option Exercise	0.00	14,250	0	1,811,398	Jan 07 09:32 PM
Car Bruce	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	4,750	0	10,096	Jan 07 09:32 PM
Clark George C.	VP, Chief Accounting Officer	Jan 05 '26	Option Exercise	0.00	2,500	0	68,095	Jan 07 09:31 PM
Clark George C.	VP, Chief Accounting Officer	Nov 17 '25	Buy	8.52	17,000	144,770	20,000	Nov 18 07:29 AM
Bailey Gregory	Director	Nov 13 '25	Buy	7.50	400,000	3,000,000	2,020,071	Nov 17 07:31 AM
CHILDS JOHN W	Director	Nov 13 '25	Buy	7.50	3,333,333	24,999,998	5,653,904	Nov 17 07:30 AM
Coric Vlad	Chief Executive Officer	Nov 13 '25	Buy	7.50	666,666	4,999,995	1,195,275	Nov 17 07:30 AM
CHILDS JOHN W	Director	Mar 04 '25	Buy	30.47	32,700	996,238	2,320,571	Mar 05 07:01 AM

Open in Screener

ANVS

Annovis Bio Inc

Feb 13 • 04:00PM ET

2.37

-0.06 -2.47 %

Healthcare • Biotechnology • USA • NYSE

Peers: BIIB ACAD AXSM SAVA NBIX AVXL NERV PRTA PRQR RNA

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-1.48	Insider Own	15.45%	Shs Outstand	26.50M	Perf Week	-4.82%
Market Cap	62.80M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	41.09%	Shs Float	22.41M	Perf Month	-25.24%
Enterprise Value	47.51M	PEG	-	EPS next Q	-0.31	Inst Own	18.13%	Short Float	13.10%	Perf Quarter	-2.47%
Income	-24.88M	P/S	-	EPS this Y	43.52%	Inst Trans	7.40%	Short Ratio	1.79	Perf Half Y	-12.87%
Sales	0.00M	P/B	3.64	EPS next Y	0.22%	ROA	-157.74%	Short Interest	2.94M	Perf YTD	-31.50%
Book/sh	0.65	P/C	4.11	EPS next 5Y	18.51%	ROE	-246.14%	52W High	5.50 -56.91%	Perf Year	-8.85%
Cash/sh	0.58	P/FCF	-	EPS past 3/5Y	-6.68% -73.95%	ROIC	-189.15%	52W Low	1.11 113.51%	Perf 3Y	-88.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.13% 7.96%	Perf 5Y	-89.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	62.84%	Oper. Margin	-	ATR (14)	0.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.60	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	31.97	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	62.13%	SMA20	-12.08%	Beta	1.33	Target Price	12.50
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-29.62%	Rel Volume	0.13	Prev Close	2.43
Employees	8	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-11.71%	Avg Volume	1.64M	Price	2.37
IPO	Jan 29, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	1.78% -	Trades		Volume	216,558	Change	-2.47%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-10-25	Downgrade	D. Boral Capital	Buy → Hold
Oct-25-24	Upgrade	Maxim Group	Hold → Buy	$25
Dec-29-23	Initiated	Canaccord Genuity	Buy	$36
Jul-07-21	Reiterated	Maxim Group	Buy	$45 → $150

Feb-12-26 08:00AM	Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer's Disease (GlobeNewswire)
Dec-18-25 04:35PM	Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients (GlobeNewswire)
Dec-16-25 08:00AM	Annovis to Host Corporate Update Webinar on January 28, 2026 (GlobeNewswire)
Dec-03-25 08:00AM	Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group (GlobeNewswire) +5.44%
Nov-24-25 08:00AM	Annovis Announces Two Presentations at the CTAD 2025 Conference (GlobeNewswire) +7.92%
08:00AM	Loading…
Nov-18-25 08:00AM	Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study (GlobeNewswire) +11.22%
Nov-17-25 08:00AM	Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients (GlobeNewswire) +29.49%
Nov-12-25 08:00AM	Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results (GlobeNewswire) +15.17%
Nov-06-25 08:00AM	Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer's Program (GlobeNewswire)
Oct-27-25 08:00AM	Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules (GlobeNewswire)
Oct-15-25 05:15PM	Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock (GlobeNewswire) +7.74% +12.15%
Oct-10-25 08:31AM	Annovis Announces $6 Million Registered Direct Offering of Common Stock (GlobeNewswire) -22.73%
Oct-09-25 07:30AM	Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment (GlobeNewswire)
Sep-25-25 07:30AM	Annovis Appoints Mark Guerin as Chief Financial Officer (GlobeNewswire)
Sep-16-25 07:30AM	Annovis Reports Peer-Reviewed Publication Highlighting Pharmacokinetics of Novel Crystal Buntanetap (GlobeNewswire)
08:00AM	Loading…
Sep-02-25 08:00AM	Annovis to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-29-25 07:24AM	Annovis (ANVS) Secures Patent Coverage for Both Forms of Buntanetap (Insider Monkey)
Aug-12-25 04:05PM	Annovis Provides Corporate Updates and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-07-25 08:00AM	Annovis Completes Full Patent Transfer to Crystal Buntanetap (GlobeNewswire)
Jun-26-25 08:00AM	Annovis to Attend the AAIC 2025 with Four Poster Presentations (GlobeNewswire) -5.24%
Jun-19-25 06:30AM	Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance (GlobeNewswire)
Jun-11-25 12:00PM	All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy (Zacks)
Jun-05-25 08:00AM	Annovis to Host Webinar and Live Q&A on June 24, 2025 (GlobeNewswire) -5.86%
May-13-25 04:30PM	Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results (GlobeNewswire) +9.68%
Apr-29-25 08:00AM	Annovis Bio Appoints Hui Liu as Director of Biostatistics (GlobeNewswire) -5.16%
Mar-27-25 04:30PM	Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE (GlobeNewswire) -10.81%
Mar-25-25 08:00AM	Annovis to Attend AD/PD 2025 with Extensive Scientific Program (GlobeNewswire) +6.49%
Mar-21-25 05:05PM	Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results (GlobeNewswire) +5.71%
Mar-11-25 08:00AM	Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment (GlobeNewswire)
Feb-19-25 08:30AM	Annovis to Host Patients' Live Forum on February 27, 2025 (GlobeNewswire) -6.85%
08:00AM	Loading…
Feb-07-25 08:00AM	Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-06-25 11:21AM	Annovis begins treatment of subjects in Alzheimers trial (Clinical Trials Arena)
08:20AM	Annovis Bio announces first patients entered Phase 3 study of buntanetap (TipRanks)
Feb-05-25 08:00AM	Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease (GlobeNewswire)
Feb-04-25 04:31PM	Annovis Bio, Inc. Announces Closing of $21 Million Public Offering (GlobeNewswire)
Feb-03-25 06:22AM	Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering (GlobeNewswire) -33.47%
Jan-31-25 08:14PM	Annovis Bio, Inc. Announces Proposed Public Offering (GlobeNewswire)
Jan-15-25 08:11AM	Annovis Bio granted U.S. patent covering buntanetap (TipRanks)
Jan-14-25 08:00AM	Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection (GlobeNewswire)
Jan-07-25 08:00AM	FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer's Disease Study, Streamlining Development Pathway (GlobeNewswire) -5.61%
Dec-05-24 08:30AM	Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace (GlobeNewswire)
Dec-04-24 02:21PM	Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace (PR Newswire) -6.42%
Nov-25-24 08:00AM	Annovis to Host Year-End Investor Webcast on December 11, 2024 (GlobeNewswire) +6.32%
Nov-12-24 08:00AM	Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB) (GlobeNewswire)
Nov-11-24 08:00AM	Annovis Bio Reports Third Quarter Financial Results and Provides Business Update (GlobeNewswire) -6.25%
Nov-07-24 08:00AM	Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist (GlobeNewswire)
Oct-31-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio (GlobeNewswire)
Oct-22-24 08:00AM	Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 (GlobeNewswire)
Oct-17-24 10:52AM	Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug (GuruFocus.com) -5.25%
Oct-15-24 08:00AM	FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs (GlobeNewswire) +6.26%
Oct-03-24 08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
08:30AM	Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases (GlobeNewswire)
Oct-02-24 08:30AM	Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations (GlobeNewswire) +5.42%
Sep-30-24 08:00AM	Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra (GlobeNewswire)
Sep-05-24 08:00AM	Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -6.76%
Aug-15-24 07:00AM	Annovis Bio Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) +14.05%
Aug-06-24 09:00AM	Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities (GlobeNewswire)
08:30AM	Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033 (GlobeNewswire)
08:00AM	Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist (GlobeNewswire)
Aug-05-24 08:00AM	IBN Announces Latest Episode of The Bell2Bell Podcast Featuring Annovis Bio CEO Dr. Maria Maccecchini, Live from AAIC 2024 (GlobeNewswire)
Jul-24-24 08:00AM	Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap (GlobeNewswire)
Jul-16-24 08:00AM	Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap (GlobeNewswire)
Jul-09-24 08:00AM	Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team (GlobeNewswire) -5.76%
Jul-03-24 12:53PM	Annovis stock swells after Phase III Parkinsons subgroup success (Clinical Trials Arena) -12.93%
12:21PM	Annovis Bio shares dip on phase III Parkinson's trial data (Yahoo Finance Video)
09:10AM	Annovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study (Zacks)
Jul-02-24 04:45PM	Why Did Annovis Bio (ANVS) Stock Close Up 80% Today? (InvestorPlace) +76.09%
08:00AM	Annovis Bio Announces New Data from Phase III Parkinson's Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap (GlobeNewswire)
Jun-27-24 08:00AM	Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap (GlobeNewswire)
Jun-26-24 08:00AM	Annovis Bio Files Patent for New Composition of Matter for Buntanetap (GlobeNewswire)
Jun-25-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data (GlobeNewswire) -8.70%
Jun-18-24 08:00AM	Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference 2024 (GlobeNewswire)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE) -5.81%
Jun-11-24 08:00AM	Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients (GlobeNewswire)
Jun-05-24 08:00AM	Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast (GlobeNewswire)
May-28-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet (Zacks) -8.78%
May-21-24 07:30AM	Annovis Announces New Publication in a Peer-Reviewed Journal (GlobeNewswire) -5.94%
May-13-24 01:53PM	ANVS Stock Earnings: Annovis Bio Beats EPS for Q1 2024 (InvestorPlace) +15.51%
07:30AM	Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson's Disease (GlobeNewswire) +25.10%
May-06-24 07:30AM	Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders (GlobeNewswire)
Apr-30-24 10:17AM	Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating (MT Newswires) -23.49%
Apr-29-24 02:54PM	Top Midday Decliners (MT Newswires) -59.58%
12:12PM	Annovis Bio Shares Tumble After Drug Candidate Buntanetap for Alzheimer's Misses Efficacy Endpoint in Phase 2/3 Study (MT Newswires)
10:51AM	UPDATE 3-Annovis tumbles as Alzheimer's treatment misses in mid-stage study (Reuters)
10:20AM	CORRECTED- Annovis Bio fails to meet main goal of mid-stage Alzheimer's treatment trial (Reuters)
10:10AM	Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer's Disease (GlobeNewswire)
Apr-24-24 09:55AM	Wall Street Analysts Believe Annovis Bio (ANVS) Could Rally 197.98%: Here's is How to Trade (Zacks) +7.24%
Apr-08-24 09:55AM	Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High? (Zacks)
Apr-02-24 12:53PM	ANVS Stock Earnings: Annovis Bio Misses EPS for Q4 2023 (InvestorPlace) -6.52%
07:30AM	Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Apr-01-24 08:00AM	Annovis Announces Publication That Supports Understanding of Buntanetap's Mechanism of Action in Humans (GlobeNewswire)
Mar-21-24 09:55AM	Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet (Zacks) +6.58%
Mar-20-24 07:30AM	Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire) +24.44%
Mar-18-24 08:52AM	Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock? (Zacks)
Mar-06-24 03:33PM	Sell Signal: 3 Stocks to Unload Before the Bubble Bursts (InvestorPlace)
Feb-27-24 08:00AM	Annovis Bio Announces Participation in Forum Discussion at AD/PD 2024 (GlobeNewswire) +10.37%
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey) -10.76%
Feb-14-24 07:30AM	Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer's Disease (GlobeNewswire)
Feb-12-24 04:06PM	3 Growth Stocks to Sell in February Before They Bottom (InvestorPlace) -5.10%

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hoffman Michael B	Director	Dec 08 '25	Buy	4.31	45,000	193,794	2,574,739	Dec 08 08:05 PM
Hoffman Michael B	Director	Nov 24 '25	Buy	4.08	39,200	159,886	2,519,739	Nov 25 12:26 PM
Hoffman Michael B	Director	Nov 21 '25	Buy	3.50	20,000	69,900	2,490,539	Nov 21 07:57 PM
Hoffman Michael B	Director	Nov 14 '25	Buy	2.11	15,000	31,650	2,470,539	Nov 18 07:44 AM
Maccecchini Maria-Luisa	President & CEO	Oct 28 '25	Buy	2.05	97,561	200,000	1,212,020	Nov 12 09:19 AM
Hoffman Michael B	Director	Oct 28 '25	Buy	2.05	975,610	2,000,000	2,455,539	Nov 12 09:18 AM
Bruck Claudine	Director	Sep 10 '25	Option Exercise	0.14	7,142	1,000	13,709	Nov 12 09:17 AM

SONO

Sonos Inc

ARX

Accelerant Holdings

DGICA

Donegal Group Inc

SUNC

SunocoCorp LLC

BHVN

Biohaven Ltd

ANVS

Annovis Bio Inc

Upgrade your FINVIZ experience